BBIO
BridgeBio Pharma Inc

5,301
Loading...
Loading...
News
all
press releases
Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth?
Alnylam's strong drug sales and advancing partnerships with Regeneron and Roche highlight key growth drivers in the quarters ahead.
Zacks·20d ago
News Placeholder
More News
News Placeholder
Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?
ALNY's Amvuttra revenues surge with 89% sales growth in H1 and a key label expansion, but faces tough competition in the ATTR-CM market.
Zacks·1mo ago
News Placeholder
BridgeBio Pharma (BBIO) Reports Q2 Loss, Beats Revenue Estimates
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -14.46% and +14.95%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2mo ago
News Placeholder
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy?
BridgeBio Pharma (BBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2mo ago
News Placeholder
Starbucks, Freeport-McMoran and Verona Pharma rise premarket; WPP, T-Mobile fall
Investing.com -- U.S. stock futures edged higher Wednesday in calm trading, as investors assessed the new developments in the Trump administration’s trade negotiations ahead of the release of the minutes from the last Federal Reserve meeting.
investing.com·3mo ago
News Placeholder
Bayer Begins Phase I Study on BAY 3670549 in Atrial Fibrillation
Zacks·4mo ago
News Placeholder
Are Medical Stocks Lagging Alignment Healthcare (ALHC) This Year?
Zacks·4mo ago
News Placeholder
Wall Street Analysts Believe BridgeBio Pharma (BBIO) Could Rally 63.87%: Here's is How to Trade
Zacks·5mo ago
News Placeholder
Is This Biotech Stock With 150% Upside a Buy Now?
The high price estimate for BridgeBio Pharma suggests potential upside of 150% in 2025.
barchart.com·9mo ago

Latest BBIO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.